Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements
- PMID: 37409250
- PMCID: PMC10319053
- DOI: 10.3389/fonc.2023.1176950
Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements
Abstract
Colorectal cancer results in the deaths of hundreds of thousands of patients worldwide each year, with incidence expected to rise over the next two decades. In the metastatic setting, cytotoxic therapy options remain limited, which is reflected in the meager improvement of patient survival rates. Therefore, focus has turned to the identification of the mutational composition inherent to colorectal cancers and development of therapeutic targeted agents. Herein, we review the most up to date systemic treatment strategies for metastatic colorectal cancer based on the actionable molecular alterations and genetic profiles of colorectal malignancies.
Keywords: EGFR inhibitor; HER2; KRAS; metastatic colorectal cancer; mismatch repair.
Copyright © 2023 Cann, LaPelusa, Cimino and Eng.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Targeted therapy for metastatic colorectal cancer.Expert Rev Anticancer Ther. 2018 Oct;18(10):991-1006. doi: 10.1080/14737140.2018.1502664. Epub 2018 Aug 3. Expert Rev Anticancer Ther. 2018. PMID: 30019590 Review.
-
Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.JAMA. 2021 Feb 16;325(7):669-685. doi: 10.1001/jama.2021.0106. JAMA. 2021. PMID: 33591350 Review.
-
Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.J Med Econ. 2022 Jan-Dec;25(1):817-825. doi: 10.1080/13696998.2022.2080463. J Med Econ. 2022. PMID: 35593483
-
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.Eur J Cancer. 2021 Sep;155:73-84. doi: 10.1016/j.ejca.2021.06.037. Epub 2021 Aug 5. Eur J Cancer. 2021. PMID: 34365081
-
Precision medicine for metastatic colorectal cancer: an evolving era.Expert Rev Gastroenterol Hepatol. 2019 Oct;13(10):919-931. doi: 10.1080/17474124.2019.1663174. Epub 2019 Sep 3. Expert Rev Gastroenterol Hepatol. 2019. PMID: 31475851 Review.
Cited by
-
Molecular Landscape and Therapeutic Strategies against Colorectal Cancer.Cancers (Basel). 2024 Apr 18;16(8):1551. doi: 10.3390/cancers16081551. Cancers (Basel). 2024. PMID: 38672633 Free PMC article. Review.
-
Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database.Front Pharmacol. 2024 Jul 23;15:1399998. doi: 10.3389/fphar.2024.1399998. eCollection 2024. Front Pharmacol. 2024. PMID: 39108741 Free PMC article.
-
A nomogram construction and multicenter validation for predicting overall survival after fruquintinib application in patients with metastatic colorectal cancer: a multicenter retrospective study.Therap Adv Gastroenterol. 2024 Oct 8;17:17562848241284229. doi: 10.1177/17562848241284229. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 39386273 Free PMC article.
-
Evaluation of the efficacy and safety of first- and second-line immunotherapy in patients with metastatic colorectal cancer: a systematic review and network meta-analysis based on randomized controlled trials.Front Immunol. 2024 Sep 18;15:1439624. doi: 10.3389/fimmu.2024.1439624. eCollection 2024. Front Immunol. 2024. PMID: 39359729 Free PMC article.
References
-
- National Cancer Institute . SEER cancer stat facts: colorectal cancer (2022). Available at: https://seer.cancer.gov/statfacts/html/colorect.html.
-
- Crooke H, Kobayashi M, Mitchell B, Nwokeji E, Laurie M, Kamble S, et al. . Estimating 1- and 5-year relative survival trends in colorectal cancer (CRC) in the united states: 2004 to 2014. J Clin Oncol (2018) 36(4_suppl):587–. doi: 10.1200/JCO.2018.36.4_suppl.587 - DOI
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous